vs
Side-by-side financial comparison of AMN HEALTHCARE SERVICES INC (AMN) and EXELIXIS, INC. (EXEL). Click either name above to swap in a different company.
AMN HEALTHCARE SERVICES INC is the larger business by last-quarter revenue ($748.2M vs $598.7M, roughly 1.2× EXELIXIS, INC.). EXELIXIS, INC. runs the higher net margin — 40.8% vs -1.0%, a 41.9% gap on every dollar of revenue. On growth, EXELIXIS, INC. posted the faster year-over-year revenue change (5.6% vs 1.8%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $67.6M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs -4.5%).
AMN Healthcare Services Inc. is a leading US healthcare sector workforce solutions and staffing provider. It offers temporary and permanent placement for nurses, physicians, allied health and other clinical/non-clinical staff, plus workforce management tools and consulting for hospitals, clinics and other medical facilities.
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
AMN vs EXEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $748.2M | $598.7M |
| Net Profit | $-7.7M | $244.5M |
| Gross Margin | 26.1% | 95.6% |
| Operating Margin | 1.1% | 39.3% |
| Net Margin | -1.0% | 40.8% |
| Revenue YoY | 1.8% | 5.6% |
| Net Profit YoY | 95.9% | 74.8% |
| EPS (diluted) | $-0.19 | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $598.7M | ||
| Q4 25 | $748.2M | $597.8M | ||
| Q3 25 | $634.5M | $568.3M | ||
| Q2 25 | $658.2M | $555.4M | ||
| Q1 25 | $689.5M | $566.8M | ||
| Q4 24 | $734.7M | — | ||
| Q3 24 | $687.5M | $539.5M | ||
| Q2 24 | $740.7M | $637.2M |
| Q1 26 | — | $244.5M | ||
| Q4 25 | $-7.7M | $193.6M | ||
| Q3 25 | $29.3M | $184.8M | ||
| Q2 25 | $-116.2M | $159.6M | ||
| Q1 25 | $-1.1M | $139.9M | ||
| Q4 24 | $-187.5M | — | ||
| Q3 24 | $7.0M | $118.0M | ||
| Q2 24 | $16.2M | $226.1M |
| Q1 26 | — | 95.6% | ||
| Q4 25 | 26.1% | 96.9% | ||
| Q3 25 | 29.1% | 96.6% | ||
| Q2 25 | 29.8% | 96.5% | ||
| Q1 25 | 28.7% | 96.5% | ||
| Q4 24 | 29.8% | — | ||
| Q3 24 | 31.0% | 96.8% | ||
| Q2 24 | 31.0% | 97.2% |
| Q1 26 | — | 39.3% | ||
| Q4 25 | 1.1% | 39.6% | ||
| Q3 25 | 7.5% | 37.6% | ||
| Q2 25 | -18.8% | 33.6% | ||
| Q1 25 | 1.8% | 28.8% | ||
| Q4 24 | -27.6% | — | ||
| Q3 24 | 3.2% | 25.2% | ||
| Q2 24 | 5.1% | 43.3% |
| Q1 26 | — | 40.8% | ||
| Q4 25 | -1.0% | 32.4% | ||
| Q3 25 | 4.6% | 32.5% | ||
| Q2 25 | -17.7% | 28.7% | ||
| Q1 25 | -0.2% | 24.7% | ||
| Q4 24 | -25.5% | — | ||
| Q3 24 | 1.0% | 21.9% | ||
| Q2 24 | 2.2% | 35.5% |
| Q1 26 | — | $0.89 | ||
| Q4 25 | $-0.19 | $0.69 | ||
| Q3 25 | $0.76 | $0.65 | ||
| Q2 25 | $-3.02 | $0.55 | ||
| Q1 25 | $-0.03 | $0.47 | ||
| Q4 24 | $-4.90 | — | ||
| Q3 24 | $0.18 | $0.40 | ||
| Q2 24 | $0.42 | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $34.0M | $1.1B |
| Total DebtLower is stronger | $767.1M | — |
| Stockholders' EquityBook value | $642.1M | $2.2B |
| Total Assets | $2.1B | $2.8B |
| Debt / EquityLower = less leverage | 1.19× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.1B | ||
| Q4 25 | $34.0M | $988.5M | ||
| Q3 25 | $52.6M | $791.1M | ||
| Q2 25 | $41.5M | $1.0B | ||
| Q1 25 | $55.8M | $1.1B | ||
| Q4 24 | $10.6M | — | ||
| Q3 24 | $30.6M | $1.2B | ||
| Q2 24 | $48.0M | $1.0B |
| Q1 26 | — | — | ||
| Q4 25 | $767.1M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $2.2B | ||
| Q4 25 | $642.1M | $2.2B | ||
| Q3 25 | $644.4M | $2.0B | ||
| Q2 25 | $607.6M | $2.1B | ||
| Q1 25 | $715.1M | $2.2B | ||
| Q4 24 | $706.6M | — | ||
| Q3 24 | $890.7M | $2.3B | ||
| Q2 24 | $876.9M | $2.1B |
| Q1 26 | — | $2.8B | ||
| Q4 25 | $2.1B | $2.8B | ||
| Q3 25 | $2.1B | $2.7B | ||
| Q2 25 | $2.2B | $2.8B | ||
| Q1 25 | $2.4B | $2.9B | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.7B | $3.0B | ||
| Q2 24 | $2.8B | $2.8B |
| Q1 26 | — | — | ||
| Q4 25 | 1.19× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $75.6M | $333.5M |
| Free Cash FlowOCF − Capex | $67.6M | $332.4M |
| FCF MarginFCF / Revenue | 9.0% | 55.5% |
| Capex IntensityCapex / Revenue | 1.1% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 1.36× |
| TTM Free Cash FlowTrailing 4 quarters | $233.8M | $875.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $333.5M | ||
| Q4 25 | $75.6M | $290.3M | ||
| Q3 25 | $22.7M | $49.0M | ||
| Q2 25 | $78.5M | $211.4M | ||
| Q1 25 | $92.7M | $240.3M | ||
| Q4 24 | $72.8M | — | ||
| Q3 24 | $66.7M | $271.3M | ||
| Q2 24 | $99.5M | $119.5M |
| Q1 26 | — | $332.4M | ||
| Q4 25 | $67.6M | $288.8M | ||
| Q3 25 | $14.8M | $46.2M | ||
| Q2 25 | $68.7M | $208.5M | ||
| Q1 25 | $82.7M | $236.3M | ||
| Q4 24 | $56.6M | — | ||
| Q3 24 | $47.4M | $263.1M | ||
| Q2 24 | $72.2M | $113.0M |
| Q1 26 | — | 55.5% | ||
| Q4 25 | 9.0% | 48.3% | ||
| Q3 25 | 2.3% | 8.1% | ||
| Q2 25 | 10.4% | 37.5% | ||
| Q1 25 | 12.0% | 41.7% | ||
| Q4 24 | 7.7% | — | ||
| Q3 24 | 6.9% | 48.8% | ||
| Q2 24 | 9.8% | 17.7% |
| Q1 26 | — | 0.2% | ||
| Q4 25 | 1.1% | 0.2% | ||
| Q3 25 | 1.2% | 0.5% | ||
| Q2 25 | 1.5% | 0.5% | ||
| Q1 25 | 1.4% | 0.7% | ||
| Q4 24 | 2.2% | — | ||
| Q3 24 | 2.8% | 1.5% | ||
| Q2 24 | 3.7% | 1.0% |
| Q1 26 | — | 1.36× | ||
| Q4 25 | — | 1.50× | ||
| Q3 25 | 0.77× | 0.27× | ||
| Q2 25 | — | 1.32× | ||
| Q1 25 | — | 1.72× | ||
| Q4 24 | — | — | ||
| Q3 24 | 9.54× | 2.30× | ||
| Q2 24 | 6.13× | 0.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMN
| Travel Nurse Staffing | $208.3M | 28% |
| Allied Staffing | $146.9M | 20% |
| Labor Disruption Services | $124.3M | 17% |
| Technology And Workforce Solutions | $88.0M | 12% |
| Language Services | $69.9M | 9% |
| Other | $29.6M | 4% |
| International Nurse Staffing | $29.6M | 4% |
| Interim Leadership Staffing | $24.1M | 3% |
| Vendor Management Systems | $16.3M | 2% |
| Local Staffing | $8.6M | 1% |
| International Nurse Permanent Placement | $2.6M | 0% |
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
